Talal AH, Venuto CS, Younis I. Assessment of hepatic impairment and implications for pharmacokinetics of substance use treatment. Clin Pharmacol Drug Dev. 2017;6(2):206–12. https://doi.org/10.1002/cpdd.336.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sahre MD, Milligan L, Madabushi R, Graham RA, Reynolds KS, Terzic A, et al. Evaluating patients with impaired renal function during drug development: highlights from the 2019 US FDA pharmaceutical science and clinical pharmacology advisory committee meeting. Clin Pharmacol Ther. 2021;110(2):285–8. https://doi.org/10.1002/cpt.2151.

Article  PubMed  Google Scholar 

Sun Q, Seo S, Zvada S, Liu C, Reynolds K. Does hepatic impairment affect the exposure of monoclonal antibodies? Clin Pharmacol Ther. 2020;107(5):1256–62. https://doi.org/10.1002/cpt.1765.

Article  CAS  PubMed  Google Scholar 

Meibohm B, Zhou H. Characterizing the impact of renal impairment on the clinical pharmacology of biologics. J Clin Pharmacol. 2012;52(1 Suppl):54S-62S. https://doi.org/10.1177/0091270011413894.

Article  PubMed  Google Scholar 

Mahmood I, Pettinato M. Impact of intrinsic and extrinsic factors on the pharmacokinetics of peptides: when is the assessment of certain factors warranted? Antibodies. 2022;11(1):1.

Article  CAS  Google Scholar 

Administration UFaD. Federal register: definition of the term “biological product”. 2020; Available from: https://www.federalregister.gov/documents/2020/02/21/2020-03505/definition-of-the-term-biological-product.

Zhao L, Ren TH, Wang DD. Clinical pharmacology considerations in biologics development. Acta Pharmacol Sin. 2012;33(11):1339–47. https://doi.org/10.1038/aps.2012.51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Diao L, Meibohm B. Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides. Clin Pharmacokinet. 2013;52(10):855–68. https://doi.org/10.1007/s40262-013-0079-0.

Article  CAS  PubMed  Google Scholar 

Czock D, Keller F, Seidling HM. Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs. Br J Clin Pharmacol. 2012;74(1):66–74. https://doi.org/10.1111/j.1365-2125.2012.04172.x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26(10):2700–7. https://doi.org/10.1016/j.bmc.2017.06.052.

Article  CAS  PubMed  Google Scholar 

Yayne D, Yiu V. Hematuria and Proteinuria. In: National Kidney Foundation Primer on Kidney Diseases (Sixth Edition). In: Gilbert SJ, Weiner DE, editors. 2014, p. 42–50. https://doi.org/10.1016/B978-1-4557-4617-0.00005-4.

de Souza DB, Gregório BM, Benchimol M, Nascimento FA de M. Evaluation of the Glomerular Filtration Barrier by Electron Microscopy. In: Modern Electron Microscopy in Physical and Life Sciences. In Tech. 2016. https://doi.org/10.5772/61811.

Venturoli D, Rippe B. Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability. Am J Physiol Renal Physiol. 2005;288(4):605–13. https://doi.org/10.1152/ajprenal.00171.2004.

Article  CAS  Google Scholar 

Ohlson M, Sorensson J, Lindstrom K, Blom AM, Fries E, Haraldsson B. Effects of filtration rate on the glomerular barrier and clearance of four differently shaped molecules. Am J Physiol Renal Physiol. 2001;281(1):F103–13. https://doi.org/10.1152/ajprenal.2001.281.1.F103.

Article  CAS  PubMed  Google Scholar 

Akizawa H, Uehara T, Arano Y. Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins. Adv Drug Deliv Rev. 2008;60(12):1319–28. https://doi.org/10.1016/j.addr.2008.04.005.

Article  CAS  PubMed  Google Scholar 

US Food and Drug Administration. Guidance for industry (draft) - pharmacokinetics in patients with Impaired renal function — study design, data analysis, and impact on dosing and labeling. 2020. https://www.fda.gov/media/78573/download.

Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis. 2003;23(Suppl 1):23–8. https://doi.org/10.1055/s-2003-41631.

Article  PubMed  Google Scholar 

Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019;10:155. https://doi.org/10.3389/fendo.2019.00155.

Article  Google Scholar 

Fogueri U, Cheungapasitporn W, Bourne D, Fervenza FC, Joy MS. Rituximab exhibits altered pharmacokinetics in patients with membranous nephropathy. Ann Pharmacother. 2019;53(4):357–63. https://doi.org/10.1177/1060028018803587.

Article  CAS  PubMed  Google Scholar 

Roberts BV, Susano I, Gipson DS, Trachtman H, Joy MS. Contribution of renal and non-renal clearance on increased total clearance of adalimumab in glomerular disease. J Clin Pharmacol. 2013;53(9):919–24. https://doi.org/10.1002/jcph.121.

Article  CAS  PubMed  Google Scholar 

US prescribing information for lisinopril. 2021; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/019558s063lbl.pdf.

US prescribing information for enalapril. 2018; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018998s083lbl.pdf.

US prescribing information for ixazomib. 2022; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208462s012s013lbl.pdf.

US prescribing information for carfilzomib. 2022; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202714s034lbl.pdf.

US prescribing information for eptifibatide. 2021; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020718s039lbl.pdf.

US prescribing information for octreotide acetate 2022; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/019667s073lbl.pdf.

US prescribing information for bremelanotide 2020; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210557s002lbl.pdf.

US prescribing information for lanreotide. 2019; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022074s024lbl.pdf.

US prescribing information for setmelanotide. 2022; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213793s001lbl.pdf.

US prescribing information for desmopressin. 2018.

US prescribing information for cyclosporine. 2015; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050573s041,050574s051,050625s055lbl.pdf

US prescribing information for voclosporin. 2021; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213716s000lbl.pdf.

US prescribing information for goserelin. 2015; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019726s059,020578s037lbl.pdf.

US prescribing information for triptorelin. 2018; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020715s040,021288s035,022427s015lbl.pdf.

US prescribing information for bivalirudin. 2021; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208374s002lbl.pdf.

US prescribing information for liraglutide. 2022; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022341s037s038lbl.pdf.

US prescribing information for teduglutide 2021; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203441s018lbl.pdf.

US prescribing information for abaloparatide. 2021; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208743s010lbl.pdf.

US prescribing information for teriparatide. 2021; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208743s010lbl.pdf.

US prescribing information for exenatide. 2022; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021773s046s047lbl.pdf.

US prescribing information for lixisenatide. 2021; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208471s004lbl.pdf.

US prescribing information for desirudin. 2014; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021271s006lbl.pdf.

US prescribing information for anakinra. 2020; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/103950s5189lbl.pdf.

US prescribing information for peginterferon alfa-2b. 2014; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/103949s5313lbl.pdf.

US prescribing information for peginterferon beta-1a. 2022; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125499s025lbl.pdf.

US Prescribing information for dulaglutide. 2022; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125469s046s052lbl.pdf.

US prescribing information for brentuximab vedotin. 2019; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125388s100lbl.pdf.

Liu SN, Li C. Clinical pharmacology strategies in supporting drug development and approval of antibody-drug conjugates in oncology. Cancer Chemother Pharmacol. 2021;87(6):743–65. https://doi.org/10.1007/s00280-021-04250-0.

Article  PubMed  PubMed Central  Google Scholar 

Schadt S, Hauri S, Lopes F, Edelmann MR, Staack RF, Villasenor R, et al. Are biotransformation studies of therapeutic proteins needed? Scientific considerations and technical challenges. Drug Metab Dispos. 2019;47(12):1443–56. https://doi.org/10.1124/dmd.119.088997.

Article  CAS  PubMed  Google Scholar 

Werle M, Bernkop-Schnurch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006;30(4):351–67. https://doi.org/10.1007/s00726-005-0289-3.

Article  CAS  PubMed  Google Scholar 

US Food and Drug Administration. Guidance for industry - pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. 2003. https://www.fda.gov/media/71311/download.

Yao JF, Yang H, Zhao YZ, Xue M. Metabolism of peptide drugs and strategies to improve their metabolic stability. Curr Drug Metab. 2018;19(11):892–901. https://doi.org/10.2174/1389200219666180628171531.

Article  CAS  PubMed  Google Scholar 

Delaforge M, Bouille G, Jaouen M, Jankowski CK, Lamouroux C, Bensoussan C. Recognition and oxidative metabolism of cyclodipeptides by hepatic cytochrome P450. Peptides. 2001;22(4):557–65. https://doi.org/10.1016/s0196-9781(01)00364-3.

Article  CAS  PubMed  Google Scholar 

Watkins PB. The role of cytochromes P-450 in cyclosporine metabolism. J Am Acad Dermatol. 1990;23(6 Pt 2):1301–9; discussion 9–11. https://doi.org/10.1016/0190-9622(90)70358-o.

Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody-drug conjugates: a comprehensive review. Mol Cancer Res. 2020;18(1):3–19. https://doi.org/10.1158/1541-7786.MCR-19-0582.

Article  CAS  PubMed  Google Scholar 

US prescribing information for bortezomib. 2021; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021602s046lbl.pdf.

US prescribing information for pasireotide. 2020; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/200677s006lbl.pdf

US prescribing information for romidepsin. 2021; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022393s017lbl.pdf.

Connolly RM, Laille E, Vaishampayan U, Chung V, Kelly K, Dowlati A, et al. Phase I and Pharmacokinetic study of romidepsin in patients with cancer and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res. 2020;26(20):5329–37. https://doi.org/10.1158/1078-0432.CCR-20-1412.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang J, Shord S, Zhao H, Men Y, Rahman A. Are hepatic impairment studies necessary for therapeutic proteins? Clin Ther. 2013;35(9):1444–51. https://doi.org/10.1016/j.clinthera.2013.06.010.

Article  CAS  PubMed  Google Scholar 

Gibbs JP, Slatter JG, Egbuna O, Geller M, Hamilton L, Dias CS, et al. Evaluation of evolocumab (AMG 145), a fully human anti-PCSK9 IgG2 monoclonal antibody, in subjects with hepatic impairment. J Clin Pharmacol. 2017;57(4):513–23. https://doi.org/10.1002/jcph.832.

Article  CAS  PubMed  Google Scholar 

US prescribing information for evolocumab. 2022; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125522s033lbl.pdf.

Li C, Agarwal P, Gibiansky E, Jin JY, Dent S, Goncalves A, et al. A phase I pharmacokinetic study of trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer and normal or reduced hepatic function. Clin Pharmacokinet. 2017;56(9):1069–80. https://doi.org/10.1007/s40262-016-0496-y.

Article  CAS  PubMed  Google Scholar 

Zhao B, Chen R, O’Connor OA, Gopal AK, Ramchandren R, Goy A, et al. Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment. Br J Clin Pharmacol. 2016;82(3):696–705. https://